Dr. Gitlitz on EGFR Exon 20 Insertion Mutations in Lung Cancer

Barbara J. Gitlitz, MD
Published: Friday, Aug 28, 2015

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.

Barbara J. Gitlitz, MD, associate professor of Clinical Medicine, Keck Hospital of USC Norris Comprehensive Cancer Center, discusses treating patients with EGFR exon 20 insertion mutations in lung cancer.

 Exon 20 insertion mutations are the third most common type of EGFR mutation that patients with lung cancer present with, says Gitlitz. While this mutation will show up in a report as an EGFR mutation, it does not respond to any currently available EGFR inhibitors. It is important to be aware that a patient with an EGFR mutation has an exon 20 insertion, explains Gitlitz.

 Exon 20 insertion mutations are currently a target without a treatment, says Gitlitz. More clinical trials are needed.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x